An Integrating Immune-Related Signature to Improve Prognosis of Hepatocellular Carcinoma

Table 1

Summary of HCC patients’ clinicopathological characteristics from TCGA database.

Characteristics	Patient
	Training set		Validation set		Sum
	Amount	%	Amount	%	Amount	%
Age at diagnosis
≥60	98	52.40	103	56.28	201	54.32
<60	89	47.60	80	43.72	169	45.68
Gender
Male	133	71.12	116	63.39	249	67.30
Female	54	28.88	67	36.61	121	32.70
Clinical stage
Stage I	76	40.64	95	51.91	171	46.22
Stage II	45	24.07	40	21.85	85	22.97
Stage III	47	25.13	38	20.77	85	22.97
Stage IV	4	2.14	1	0.55	5	1.35
Others/unknown	15	8.02	9	4.92	24	6.49
Tumor grade
G1	26	13.90	29	15.85	55	14.87
G2	91	48.66	86	47.00	177	47.84
G3	63	33.69	58	31.67	121	32.70
G4	6	3.21	6	3.28	12	3.24
Others/unknown	1	0.54	4	2.20	5	1.35
Survival status
Survive	133	71.12	107	58.47	240	64.87
Death	54	28.88	76	41.53	130	35.13